Poon, Edmund <br/><br/>
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.  [electronic resource] 

 -  Journal for immunotherapy of cancer  08 2017 
 - 63 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2051-1426 
<br/><br/><label>Standard No.: </label>10.1186/s40425-017-0268-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Benzimidazoles--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Cell Line, Tumor<br/>Cellular Reprogramming--drug effects<br/>Colorectal Neoplasms--drug therapy<br/>Drug Synergism<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Mice<br/>Mutation<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Tumor Microenvironment--drug effects<br/>Xenograft Model Antitumor Assays